MK-3475A (pembrolizumab coformulated with hyaluronidase alfa)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-3475A (pembrolizumab coformulated with hyaluronidase alfa), covering 2025-07-28 to 2025-07-28. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) [Phase 3]